194 related articles for article (PubMed ID: 32214204)
1. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders.
Kaiser A; Schmidt M; Huber O; Frietsch JJ; Scholl S; Heidel FH; Hochhaus A; Müller JP; Ernst T
Leukemia; 2020 Aug; 34(8):2206-2216. PubMed ID: 32214204
[TBL] [Abstract][Full Text] [Related]
2. p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
Elf S; Blevins D; Jin L; Chung TW; Williams IR; Lee BH; Lin JX; Leonard WJ; Taunton J; Khoury HJ; Kang S
Blood; 2011 Jun; 117(25):6885-94. PubMed ID: 21527514
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
4. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
5. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.
Wagner K; Zhang P; Rosenbauer F; Drescher B; Kobayashi S; Radomska HS; Kutok JL; Gilliland DG; Krauter J; Tenen DG
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6338-43. PubMed ID: 16606850
[TBL] [Abstract][Full Text] [Related]
6. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
7. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation.
Tavor S; Park DJ; Gery S; Vuong PT; Gombart AF; Koeffler HP
J Biol Chem; 2003 Dec; 278(52):52651-9. PubMed ID: 14517214
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
Alvarez-Calderon F; Gregory MA; Pham-Danis C; DeRyckere D; Stevens BM; Zaberezhnyy V; Hill AA; Gemta L; Kumar A; Kumar V; Wempe MF; Pollyea DA; Jordan CT; Serkova NJ; Graham DK; DeGregori J
Clin Cancer Res; 2015 Mar; 21(6):1360-72. PubMed ID: 25547679
[TBL] [Abstract][Full Text] [Related]
9. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
10. Aberrantly expressed transcription factors C/EBP and SOX4 have positive effects in the development of chronic myeloid leukemia.
Dong F; Zhang G; Zhang X; Liu X; Wang N; Sun C
Mol Med Rep; 2017 Nov; 16(5):7131-7137. PubMed ID: 28901467
[TBL] [Abstract][Full Text] [Related]
11. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
12. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
13. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
14. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
[TBL] [Abstract][Full Text] [Related]
15. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
Zhu H; Yang B; Liu J; Wu W; Ling Y
Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
17. [Detection of FLT3 gene and FLT3/ITD gene mutation in chronic myeloid leukemia and its significance].
Xu B; Tian H; Zhou SY
Ai Zheng; 2004 Oct; 23(10):1218-21. PubMed ID: 15473940
[TBL] [Abstract][Full Text] [Related]
18. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
19. Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.
Kagita S; Uppalapati S; Gundeti S; Digumarti R
Jpn J Clin Oncol; 2015 Aug; 45(8):749-54. PubMed ID: 25920395
[TBL] [Abstract][Full Text] [Related]
20. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
